B. Uluata Dayanç Et Al. , "Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue," In Interdisciplinary Cancer Research , London: Springer, London/Berlin , 2022, pp.1-31.
Uluata Dayanç, B. Et Al. Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. 2022. In Interdisciplinary Cancer Research , Springer, London/Berlin , London, 1-31.
Uluata Dayanç, B., Eriş, S., & Şentürk, Ş., (2022). Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. Interdisciplinary Cancer Research (pp.1-31), London: Springer, London/Berlin .
Uluata Dayanç, Bengisu, Sude Eriş, And ŞERİF ŞENTÜRK. "Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue." In Interdisciplinary Cancer Research , 1-31. London: Springer, London/Berlin , 2022
Uluata Dayanç, Bengisu U. Et Al. "Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue." Interdisciplinary Cancer Research , Springer, London/Berlin , 2022, pp.1-31.
Uluata Dayanç, B. Eriş, S. And Şentürk, Ş. (2022) "Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue", Interdisciplinary Cancer Research . London: Springer, London/Berlin .
@bookchapter{bookchapter, author ={Bengisu Uluata Dayanç Et Al. }, chaptertitle={Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue}, booktitle={ Interdisciplinary Cancer Research}, publisher={Springer, London/Berlin }, city={London},year={2022} }